Valganciclovir as Add-on to Second Line Therapy in Patients with Recurrent Glioblastoma

Mattia Russel Pantalone (✉ mattia.pantalone@ki.se)  
Karolinska Institutet  https://orcid.org/0000-0002-2706-4683

Afsar Rahbar  
Karolinska Institute: Karolinska Institutet

Cecilia Söderberg-Naucler  
Karolinska Institutet

Giuseppe Stragliotto  
Karolinska University Hospital: Karolinska Universitetssjukhuset

Research Article

Keywords: Neuro-oncology, Glioblastoma, Cytomegalovirus, Neurosurgery, Valganciclovir

Posted Date: January 13th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1246592/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction

Glioblastoma invariably recurs despite aggressive and multimodal first line treatment and no standardized second line therapy exists. We previously reported that treatment with the antiviral drug valganciclovir as an add-on to standard therapy significantly prolonged overall survival in 102 patients with newly diagnosed glioblastoma. Here we present the results of retrospective survival analyses including patients with glioblastoma that initiated valganciclovir therapy after recurrence.

Methods

Between April 13, 2007 and March 31, 2021, 29 patients with recurrent glioblastoma received valganciclovir as an add-on to second line therapy. Contemporary controls were 111 patients with glioblastoma who received similar second line therapy at our institution. We retrospectively analyzed survival data of these patients.

Results

Patients with recurrent glioblastoma who received valganciclovir had longer median overall survival after recurrence than controls (12.1 vs 7.4 months, respectively, p=0.0017). The drug was well tolerated. Both patients who underwent re-operation and patients that were not re-operated after recurrence benefitted significantly from valganciclovir therapy. Valganciclovir prolonged survival after recurrence both in patients with an unmethylated or methylated MGMT promoter gene.

Conclusion

Valganciclovir was safe to use and prolonged median survival after recurrence of patients with recurrent glioblastoma, re-operated or not after recurrence and with methylated or unmethylated MGMT promoter gene.

Introduction

Glioblastoma (GBM) is the deadliest and most common primary brain tumour in adults with a median overall survival (OS) of only approximately 13-15 months [1, 2]. Despite aggressive treatment, such as surgical resection followed by radiotherapy and temozolomide therapy, anti-angiogenic therapy (bevacizumab) or immunotherapy, the limited success of current treatment protocols leads to very poor prognosis. GBM tumors generally become therapy resistant and recurs almost invariably after about 7 months [3]. Patients with GBM recurrence only survive about 3 months without therapy and 6-9 months with maximal second line therapy [4, 5]. As therapy success is lacking among patients with recurrent GBM, there is no consensus on treatment of recurrent GBM. While being undoubtedly effective in newly diagnosed GBM, surgical re-operation of recurrent GBM generally fails to improve survival in recurrent cases [1, 6]. However, patients with recurrence should always be evaluated individually for re-operation
since it may be effective in selected cases [7, 8]. Second line chemotherapy often include a nitrosurea-based therapy (lomustine) that confers a progression-free survival rate at 6 months of 19%, but the objective response rate is less than 10% [9]. The anti-angiogenetic drug bevacizumab, has not improved overall survival neither in newly diagnosed nor in recurrent GBM [10-14]. A temozolomide re-challenge has not led to consistent results, wherefore it is unclear whether it is beneficial for patients with recurrent GBM or not [15-17]. Re-irradiation may result in local disease control in a subgroup of patients [18-22], but this approach is burdened by high risk of neurotoxicity. Thus, due to the consistent failures in obtaining high benefit from individual therapy protocols for patients with recurrent GBM, there is no standardized effective treatment option for these patients.

End-of-life phase of patients with GBM occurs when the tumor has become resistant to the available therapies and is characterized by an inexorable decline of cognitive and motor functions with palliative care as the only resource to offer some help to these patients [23].

In 2002, Dr Cobbs reported that 100% of GBMs were infected with cytomegalovirus (CMV)[24]. This virus may affect the oncogenic potential of cells and can cause all the Hallmarks of cancer. We found that patients with low-grade CMV infection had longer overall survival (OS) than those with high-grade infection (33 vs. 13 months, p=0.036) and they had a higher 2-year survival rate (63.6% vs. 17.2%, p=0.003) [25, 26]. These observations imply that CMV may affect tumor progression and that the virus could be a new target of therapy for patients with GBM.

To determine whether antiviral therapy against CMV was safe to use and potentially could improve the outcome of patients with GBM, we enrolled 42 patients in a double-blind clinical phase I/II pilot trial to assess the safety and potential efficacy of valganciclovir treatment as add on therapy in patients with newly diagnosed GBM (VIGAS, initiated in 2006) [27]. The study was underpowered and failed its primary end point of reduced tumor growth by MRI at 6 months. However, in exploratory analyses, we observed that VIGAS patients who were treated with valganciclovir had a better prognosis; 50% of valganciclovir treated patients were alive at 2 years compared to 18% of contemporary control patients. The median OS was also longer in valganciclovir-treated patients than in controls (24.1 vs. 13.7 months, p=0.0031) [27]. In a follow up analysis of 50 patients who were treated with valganciclovir as add on to therapy, we further observed a similar highly improved survival rate [28]. As targeting CMV with valganciclovir indicates prolonged survival of patients with newly diagnosed GBM, CMV targeted therapy should be evaluated in controlled studies, to determine if it has a place in GBM treatment.

After completing the VIGAS trial and while awaiting funding to be granted to perform a clinical randomized controlled study to evaluate this therapy in patients with GBM, we offered valganciclovir to patients with GBM who requested this therapy as a compassionate therapy. The patients received valganciclovir in addition to their standard treatment, and most were treated at the Karolinska University Hospital. Today, 139 patients have so far received this therapy and they constitute a heterogeneous group of patients; 102 patients with newly diagnosed GBM (n=102), eight with secondary GBM and 29 with recurrent GBM. Among these patients, we observed that 102 patients with newly diagnosed GBM who
had been treated with valganciclovir had longer median OS (24.1 vs 13.3 months, p<0.0001) and a higher 2-year survival rate than 231 contemporary controls (49.8% vs 17.3%). Valganciclovir improved survival in patients with radical or partial resection and with tumors with an unmethylated or methylated MGMT promoter gene, and was safe to use [29]. Patients with secondary GBM receiving valganciclovir survived 19.1 months after their progression to a grade IV tumor, compared to 12.1 months in the controls (p=0.0072) [30].

A promising indication of a possible positive effect of valganciclovir in the treatment of patients with recurrent disease was suggested by Peng et al. in 2016, who showed that combined treatment of valganciclovir and bevacizumab indicated improved survival in 13 patients with recurrent GBM compared to patients treated with bevacizumab alone (n=50); the median OS after recurrence was 13 vs 8.7 months, respectively (p=0.005). The use of valganciclovir in combination with bevacizumab was reported to be well tolerated [31].

Here, we present the survival data of the patients with recurrent GBM who were treated with valganciclovir at our institution.

Materials And Methods

study design

This is a retrospective study of the outcome of 29 patients with recurrent GBM who received valganciclovir as add-on therapy to standard treatment between April 13, 2007 and May 31, 2021 at Karolinska University Hospital, in addition to second-line treatment. Twenty-five patients received valganciclovir after their first recurrence while 4 patients had received the drug after their second recurrence. Age matched-contemporary control patients (n=111) were selected among patients with recurrent GBM with available data who were treated at our institution during the same time period. No active selection was performed regarding survival outcome, therapy or other clinical characteristics. Most of the patients had asked for the valganciclovir therapy themselves after searching for different therapy options online. The primary end point was survival after recurrence calculated as the interval of time between diagnosis of recurrence and death. The study was approved by the regional ethics committee in Stockholm (Dnr: 2016/1426-31/1). The authors followed all patients throughout the study.

standard of care treatment

Patients’ demographic and clinical characteristic are summarized in Table 1. There is no standard of care for patients with recurrent GBM. Possible alternatives are reoperation, hypofractionated radiation therapy, temozolomide, lomustine (CCNU), bevacizumab, and/or gamma knife treatment. Valganciclovir was given at the standard recommended dose: 900 mg twice daily for 3 weeks followed by 900 mg daily until disease progression or palliative status.

statistical analysis
Patients were analyzed for median Survival time after recurrence, median Overall Survival (OS) time after first diagnosis, 1 and 2-year survival rates after recurrence, extent of resection and MGMT methylation status. Other parameters were age, sex, KPS score at the time of recurrence, and IDH1 mutational status. Survival data are presented in graphs as Kaplan-Meier estimates, calculated from the time of surgery or diagnosis of recurrence/progression. For the 4 patients who started valganciclovir therapy after their second recurrence, survival was calculated from the date of the second recurrence diagnosis to avoid survival bias caused by the interval of time between the first and second recurrence. All statistical hypotheses were two-sided, with a significance level of 5%. Multiple Cox regression analysis was performed to identify possible correlations among clinical and demographic variables in relation to survival. Significance was determined with a log-rank test; p<0.05 was considered significant. Graph Pad Prism (version 9) and SAS were used for statistical analyses.

Results

Between April 13, 2007 and May 31, 2021, 29 patients with recurrent GBM received valganciclovir in addition to second or third line therapy were included in the analysis. No new or additional toxicity was observed. Contemporary controls were constituted of 111 patients with recurrent disease who were all treated at our institution. Patient characteristics are summarized in Table 1.

valganciclovir in patients with recurrent disease

The median age was 54 years (range, 21 to 72 years), and 65.5% were men. The median age of the 111 controls was 57 years (range 24 to 77 years) and 64% were men. The KPS at the time of recurrence was available for all the patients included in the study and the median KPS value of both treated and control patients was 90. The median time between diagnosis of recurrent disease and start of valganciclovir was 1.8 months (range, 0 days to 7.7 months). The median length of valganciclovir therapy was 8.1 months (range, 1.5 to 147.1 months). Median survival after recurrence was longer in the valganciclovir-treated patients than in the controls (12.1 vs. 7.4 months; p=0.0017) (Fig. 1A), as was their OS from primary diagnosis (22.8 vs. 16.2 months; p=0.0014) (Fig. 1B). Remarkably, the one year survival rate was 44.8% in the valganciclovir-treated patients with primary GBM vs 23.4% among controls (p=0.0102). Two-year survival after recurrence was also much greater in the valganciclovir-treated patients (20.7% vs. 5.4%; p=0.0035). Notably, median time to progression from first diagnosis to recurrence was 8 months in controls and 7.4 months in patients subsequently treated with valganciclovir. Thus, the two groups had a comparable clinical prognosis (p=0.1992) before one group begun valganciclovir therapy, possibly giving them an improved survival chance.

Thirteen patients underwent re-operation before starting valganciclovir therapy. Survival after recurrence was significantly higher in these patients than in 35 re-operated controls (15.8 vs. 8.3 months, respectively; p=0.0083) (Fig. 2A). One-year survival rate for re-operated patients was 61.5% for patients treated with valganciclovir and 30% for controls (p=0.0683); 2 year survival rate was 23.1% in patients treated with valganciclovir and 6.7% for controls (p=0.0156). Likewise, among patients who did not
undergo a re-operation, 16 who received valganciclovir had significantly longer survival after recurrence than 76 controls (10.3 vs. 6.9 months; p=0.041) (Fig. 2B). One-year survival rate for non re-operated patients was 43.75% for patients treated with valganciclovir and 19.7% for controls (p=0.0379); 2 year survival rate was 18.75% in patients treated with valganciclovir and 5.3% for controls (p=0.0606). Re-operation provided no significant survival advantage among the controls (p=0.5928) or the valganciclovir-treated patients (p=0.7503).

Data regarding the methylation status of MGMT gene promoter was available for 48 patients in the control group and for 17 patients in the valganciclovir group. In coherence with previous published literature [32], patients in our control cohort having tumors with methylated-MGMT promoter had a longer survival after recurrence compared to patients with unmethylated MGMT promoter status (p=0.003). Among patients with a methylated MGMT promoter, median survival after recurrence was 27.35 months in valganciclovir treated patients (n=6) compared to 10.7 months in controls (n=25) (p=0.0379) (Fig. 3A). One-year survival rate was 66.7% for valganciclovir treated patients and 36% for controls (p=0.4454), and the 2-year survival rate was 66.7% versus 12%, respectively (p=0.0369). Valganciclovir seemed to provide a survival advantage also in patients with GBM with an unmethylated MGMT promoter: treated patients (n=11) survived a median of 13.3 months after recurrence compared to 6.2 months of the controls (n=23) (p=0.0076) (Fig. 3B). Valganciclovir treated patients with an unmethylated MGMT promoter had a 1-year survival rate of 54.5% compared to 8.7% for controls (p=0.0052) and the 2-year survival rate was 9.1% versus 0%, respectively (p=0.0064). In valganciclovir treated patients the difference in survival between MGMT methylated and unmethylated groups was not statistically significant (p=0.1428), possibly due to the limited number of patients in the two groups.

IDH1 mutational status was available only for 32 patients (26 controls and 6 valganciclovir treated patients); 2 of 26 analyzed patients with GBM in the control group had an IDH1 mutation, while none of the 6 analyzed tumors from valganciclovir treated patients were mutated in the IDH1 gene. Considering the lack of more data in this regard, no survival analyses were performed with IDH as a variable.

Multiple Cox regression analyses implied that methylated MGMT promoter status was the most significant variable positively associated with survival after recurrence (p < 0.0001) followed by valganciclovir treatment (p=0.001) and KPS score (p=0.005). Among these patients, gender (p=0.621), re-operation (p=0.268), and age (p=0.083) did not correlate with survival (the groups were however age-matched at inclusion). As the number of patients treated with valganciclovir in this study is relatively small (n=29), we decided to address if there could be a possible bias to our positive findings that was related to outliers. We performed a Grubbs’ test on the 29 glioblastoma patients who treated with valganciclovir; only one long-term surviving patient was identified as a significant outlier (survival after recurrence was 150.2 months, p < 0.05). We then excluded the outlier, and compared the survival after recurrence for patients receiving valganciclovir with the controls. We found that the valganciclovir treated patients still had significantly longer survival after recurrence than the controls (11.5 months vs 7.4, p=0.0064).
CMV has been shown to have a variety of negative effects in frail individuals and particularly in the elderly. To address the issue further depth, we sorted patients included in our study into two groups according to the age, with 60 years of age as a threshold. Of the 29 patients treated with valganciclovir, 11 were older than 60 (median age 61 years) and 18 were younger (median age 51 years). Among the controls, 66 patients were younger than 60 (median age 53) and 45 older (median age 63). As expected, patients older than 60 tended to have a shorter survival compared to younger patients both in controls (5.5 vs 8 months, $p=0.1658$) and in valganciclovir treated group (10.9 vs 13.85 months, $p=0.4579$), but a statistical significance was not reached possibly due to small number of patients available for analyses. We then compared survival after recurrence of older patients treated with valganciclovir to older controls and found that patients receiving valganciclovir survived significantly longer (10.9 vs 5.5 months, $p=0.0094$). Patients younger than 60 also survived longer after recurrence if they were treated with valganciclovir (13.85 vs 8 months, $p=0.0116$).

**Discussion**

In previous retrospective studies, we have showed that patients with newly diagnosed or secondary GBM seemed to survive significantly longer if they had been treated with valganciclovir as add on to standard therapy [28-30]. In the current study, we carried out a retrospective analysis on survival data for 29 patients with recurrent GBM who received valganciclovir as add on to second or third line therapy at our institution. Like in patients with primary GBM[29], we observed a distinctly increased survival rate among patients who had received valganciclovir as add on to their second (n=25) or third line therapy (n=4), as compared with contemporary control patients. All patients were treated at the same institution by the same clinical team. The median time to progression from first diagnosis to recurrence was 8 months in controls and 7.4 months in patients who subsequently were treated with valganciclovir, suggesting that the two groups had a comparable clinical prognosis ($p=0.1992$) before one group begun valganciclovir therapy that appeared to give them an improved survival chance (12.1 vs 7 months after their recurrence, $p=0.0017$). Thus, while we observed no difference in the time to tumor recurrence between patients who were later treated with valganciclovir or not, patients who received valganciclovir after their recurrence showed significantly enhanced survival rates, as compared to control patients.

The positive effect of valganciclovir therapy seemed to be most prominent in those who underwent surgery to lower their tumor burden. Patients who were operated trended to have a longer median survival after recurrence; 15.8 months compared with 10.3 months in those who did not undergo surgery, but the difference was not significant ($p=0.7503$), possibly due to low patient numbers. There was also no significant difference in survival between patients who underwent surgery or not among those who did not receive valganciclovir treatment. The median survival after recurrence was 8.3 months in patients undergoing surgery, and 6.9 months in those who were not operated ($p=0.5928$). Treatment with valganciclovir doubled the chance of being alive at one year and tripled the chance of being alive at 2 years after recurrence both in re-operated and in non re-operated patients.
Several other factors such as age, molecular phenotype and other treatments could affect the treatment results. To avoid possible bias in regards to age, the controls were age-matched with the valganciclovir treated patients at inclusion before survival analyses (median age 57 vs 54 years). We found that methylated MGMT promoter status was the most significant variable positively associated with survival after recurrence (p < 0.0001) followed by valganciclovir treatment (p=0.001). Gender or re-operation did not correlate with survival. It is well known that patients with the molecular phenotype unmethylated MGMT promoter status [33] respond poorly to therapies as they have an active MGMT enzyme that will prevent the anticipated effects of for example temozolomide therapy. The MGMT gene encodes for the enzyme O (6)-methylguanine DNA methyltransferase; when the promoter is methylated the gene is silenced. In its unmethylated state, DNA damage induced by cytotoxic drugs can rapidly be repaired by MGMT and thereby the desired cytotoxic effects induced by alkylating drugs such as temozolomide and CCNU are inhibited [34]. Patients with recurrent GBM who underwent valganciclovir treatment appeared to have prolonged survival regardless of their methylation status in the MGMT promoter. Valganciclovir therapy thereby show indications of a positive effect on survival also in patients with unmethylated MGMT promoter status, who are arguably more resistant to treatments currently in use such as alkylating agents. This is in coherence with the results of our previous study, where we showed that both patients with a methylated and unmethylated MGMT promoter status benefitted from valganciclovir therapy [29].

The KPS score is an important score relevant for survival in patients undergoing oncological therapies [35]. In this study, the patients KPS score was, as expected, associated with survival (p=0.005). Importantly, the patients treated with valganciclovir and the controls had the same median KPS at the time of recurrence thus significantly reducing the risk of having selected patients with higher possibility of surviving longer before their start of anti-viral therapy.

Goerig and colleagues recently demonstrated that patients with brain tumours who were CMV IgG positive and underwent chemo and radiotherapy often had reactivated latent CMV [36, 37]. It was proposed that the reactivated infection was primarily caused by radiation, as also patients with brain metastases who were not treated with chemotherapy reactivated CMV. If left untreated the patients’ prognosis was very poor. These findings are coherent with the data reported by Foster et al, showing a longer OS in patients with GBM who were CMV seronegative and should not be at risk for CMV reactivation [38]. It is therefore possible that patients with GBM undergoing radiotherapy reactivates a clinically relevant CMV infection and that valganciclovir therapy may be effective in treating encephalitis symptoms and clinical disease, which may affect the patient’s prognosis. These observations are in line with our previously published data demonstrating that CMV is present in brain metastases of colon and breast cancer, and that higher CMV activity is associated with worse prognosis [39, 40]. Furthermore, we recently found that radiation mimicking drugs induced expression of a set of transcription factors that can activate the CMV immediate early promoter (submitted manuscript). This may explain why DNA damage can induce reactivation of CMV. Thus, radiation induced damage may reactivate CMV in a subset of patients and valganciclovir may prevent this and positively influence survival chances among these patients. As patients with brain tumors and CMV viremia who exhibited encephalitis like symptoms...
had a poor prognosis, diagnosing CMV reactivation following radiation therapy in GBM patients is therefore important so affected patients can be treated appropriately.

Once reactivated, CMV can affect the aggressiveness of tumor cells and promote development of recurrent disease by affecting all the Hallmarks of cancer. A persistent CMV infection may be more frequent in older patients and due to the virus effects on their immune system, this virus may put higher burden older patients. Under such circumstances, the effect of valganciclovir may be enhanced in older patients. To address this issue, we examined the effect of valganciclovir in patients younger or older than 60. We observed an increase in survival after recurrence in both patients younger and older patients who received valganciclovir treatment, but this treatment seemed to be even more significant in patients older than 60 when comparing p values to younger patients ($p=0.0094$ vs $p=0.0116$). This observation suggests a possible enhanced effect of valganciclovir in elderly patients. However, the data should be taken with caution due to the limited number of patients and the lack of data concerning CMV status. These factors will be studied in the ongoing randomized clinical trial, VIGAS2, evaluating the effect of valganciclovir in patients with primary glioblastoma.

Except for this potentially promising treatment option, the situation for patients with GBM is very concerning. A number of therapies have been evaluated in the attempt to find new therapy options for patients with GBM. These include innovations for radiotherapy, strategies to overcome blood tumor barrier for delivery of chemotherapy and innovations for delivery of anti-cancer drugs [41]. Techniques and drugs have aimed to locally destruct the tumor, and different immunotherapy and cell based therapy protocols have been evaluated along with gene therapy based attempts [41]. The intratumoral heterogeneity of GBMs is high, which is likely a reason for why personalized/precision medicine so far provided limited success for these patients. So far, the many attempts to develop new therapy protocols for patients with GBM did not lead to any major breakthrough and the prognosis for patients with GBM remain utterly poor. Tumor treating fields showed improved survival in patients with newly diagnosed GBM [42], but not for patients with recurrent disease [43]. Thus, the situation for these patients is even worse and has not even led to a standardized second line therapy protocol.

Here, we demonstrate promising prolonged survival times in patients with recurrent GBM who were treated with valganciclovir as add-on to second/third line therapy. This treatment is well tolerated, with few side effects also after many years on this treatment [29]. So far, we treated 139 patients with GBM with valganciclovir and included 79 patients in a randomized placebo controlled study (NCT04116411). No new side effects have been observed, and the longest treated patient has today received the drug for over 13 years. While the number of valganciclovir treated patients with recurrent GBM is only 29 in the current study and the results should be considered with caution, the effect is similar as we reported for patients with newly diagnosed and secondary GBM, and was statistically significant, even after removal of one identified outlier. This lowers the risk of a random effect by chance. Other study limitations include potential selection bias as patients (or their relatives) selected themselves to opt for this therapy and they may hence be in better clinical condition as they were able to seek new therapy options themselves. Nevertheless, their KPS scores were similar to controls, and they had similar time to recurrence as control
patients before they started valganciclovir therapy. A strength of the study is that the patients were treated by the same physicians who followed them throughout the study and most patients in both groups received similar base line therapy.

As valganciclovir may have a potential positive effect on patients with recurrent GBM who lack any other effective treatment option, it is important to evaluate this well tolerated and potentially effective therapy in randomized clinical trials. If valganciclovir treatment turns out to be effective, it should reach patients on a global scale with no further delay.

Declarations

Funding

Supported by the Swedish Medical Research Council (VR2019-01736), Family Erling Persson´s Foundation, Sten A Olssons Foundation, BILTEMA Foundation, and Family of Jochnick´s Foundation, Stockholm County Council.

Competing Interests

CSN holds a patent for diagnostics and treatment of a variant of CMV that is often present in cancer.

Author contribution statement

GS is the main responsible neuro-oncologist caring for the patients.

Conception and design: CSN, GS, MRP.

Development of methodology and acquisition of data: MRP, GS.

Analysis and interpretation of data: MRP, AR, GS, CSN.

Writing, review and/or revision of the manuscript: MRP, AR, GS, CSN.

Administrative, technical, or material support: MRP, AR, GS and CSN.

Study supervision: GS, CSN.

All authors have read and approved the manuscript before submission.

Data Availability

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Ethics approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the regional ethics committee in Stockholm (Dnr: 2016/1426-31/1).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent to publish

The authors affirm that human research participants provided informed consent for publication of the data included in the article.

References

1. Tran B, Rosenthal MA (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 17: 417-421 doi:10.1016/j.jocn.2009.09.004
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Groups EOfrAtOBCTar, Group NCloCCT (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996 doi:10.1056/NEJMoa043330
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996 doi:10.1056/NEJMoa043330
4. Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O'Fallon JR, Jaeckle KA, Prados MD (2010) Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncology 12: 164-172 doi:10.1093/neuonc/nop019
5. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10: 162-170 doi:10.1215/15228517-2007-062
6. von Neubeck C, Seidlitz A, Kitzler HH, Beuthien-Baumann B, Krause M (2015) Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs. Br J Radiol 88: 20150354 doi:10.1259/bjr.20150354
7. Barbagallo GM, Jenkinson MD, Brodbelt AR (2008) 'Recurrent' glioblastoma multiforme, when should we reoperate? Br J Neurosurg 22: 452-455 doi:10.1080/02688690802182256
8. Tully PA, Gogos AJ, Love C, Liew D, Drummond KJ, Morokoff AP (2016) Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit. Neurosurgery 79: 678-689 doi:10.1227/neo.0000000000001338
9. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28: 1168-1174 doi:10.1200/JCO.2009.23.2595

10. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729 doi:10.1200/JCO.2007.12.2440

11. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740 doi:10.1200/JCO.2008.19.8721

12. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722 doi:10.1056/NEJMoa1308345

13. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaekle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370: 699-708 doi:10.1056/NEJMoa1308573

14. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15: 943-953 doi:10.1016/S1470-2045(14)70314-6

15. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crinò L, Ermani M, GICNO (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95: 1155-1160 doi:10.1038/sj.bjc.6603376

16. Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28: 2051-2057 doi:10.1200/JCO.2009.26.5520

17. Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY (2013) Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol 15: 930-935 doi:10.1093/neuonc/not040
18. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23: 8863-8869 doi:10.1200/JCO.2005.03.4157

19. Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5: 55 doi:10.1186/1471-2407-5-55

20. Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B, Ryu S (2009) Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol 92: 185-191 doi:10.1007/s11060-008-9752-9

21. Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28: 3048-3053 doi:10.1200/JCO.2009.25.6941

22. Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J (2013) Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol 52: 147-152 doi:10.3109/0284186X.2012.692882

23. Giannalva GR, Iacopino DG, Azzarello G, Gaggiotti C, Graziano F, Guli C, Pino MA, Maugeri R (2018) End-of-Life Care in High-Grade Glioma Patients. The Palliative and Supportive Perspective. Brain Sci 8 doi:10.3390/brainsci8070125

24. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62: 3347-3350

25. Rahbar A, Stragliotto G, Orrego A, Peredo I, Taher C, Willems J, Söderberg-Naucler C (2012) Low levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study. Herpesviridae 3: 3 doi:10.1186/2042-4280-3-3

26. Rahbar A, Orrego A, Peredo I, Dzabic M, Wolmer-Solberg N, Strååt K, Stragliotto G, Söderberg-Nauclér C (2013) Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol 57: 36-42 doi:10.1016/j.jcv.2012.12.018

27. Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, Bjarman B, Tammik C, Skarman P, Peredo I, Söderberg-Nauclér C (2013) Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer 133: 1204-1213 doi:10.1002/ijc.28111

28. Söderberg-Nauclér C, Rahbar A, Stragliotto G (2013) Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med 369: 985-986 doi:10.1056/NEJMc1302145

29. Stragliotto G, Pantalone MR, Rahbar A, Bartek J, Söderberg-Naucler C (2020) Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients. Clin Cancer Res 26: 4031-4039 doi:10.1158/1078-0432.Ccr-20-0369
30. Stragliotto G, Pantalone MR, Rahbar A, Söderberg-Nauclér C (2020) Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma. Microorganisms 8 doi:10.3390/microorganisms8101471

31. Peng C, Wang J, Tanksley JP, Mobley BC, Ayers GD, Moots PL, Clark SW (2016) Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience. Mol Clin Oncol 4: 154-158 doi:10.3892/mco.2015.692

32. Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Joudi Mashhad M, Hassanian SM, Anvari K, Avan A (2018) The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Journal of Cellular Physiology 233: 378-386 doi:https://doi.org/10.1002/jcp.25896

33. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003 doi:10.1056/NEJMoa043331

34. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Reviews Neurology 6: 39-51 doi:10.1038/nrneurol.2009.197

35. Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2: 187-193 doi:10.1200/jco.1984.2.3.187

36. Goerig NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA, Dörfler A, Engelhorn T, Eyüpoglu I, Rühle PF, Putz F, Semrau S, Gaipl US, Fietkau R (2016) Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain. Neuro Oncol 18: 1664-1672 doi:10.1093/neuonc/now120

37. Goerig NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA, Dörfler A, Engelhorn T, Eyüpoglu I, Rühle PF, Putz F, Semrau S, Gaipl US, Fietkau R (2020) Early Mortality of Brain Cancer Patients and its Connection to Cytomegalovirus Reactivation During Radiochemotherapy. Clin Cancer Res 26: 3259-3270 doi:10.1158/1078-0432.Ccr-19-3195

38. Foster H, Piper K, DePledge L, Li HF, Scanlan J, Jae-Guen Y, Boeckh M, Cobbs C (2019) Human cytomegalovirus seropositivity is associated with decreased survival in glioblastoma patients. Neurooncol Adv 1: vdz020 doi:10.1093/noajnl/vdz020

39. Taher C, de Boniface J, Mohammad AA, Religa P, Hartman J, Yaiw KC, Frisell J, Rahbar A, Söderberg-Naucler C (2013) High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS One 8: e56795 doi:10.1371/journal.pone.0056795

40. Taher C, Frisk G, Fuentes S, Religa P, Costa H, Assinger A, Vetvik KK, Bukholm IR, Yaiw KC, Smedby KE, Bäcklund M, Söderberg-Naucler C, Rahbar A (2014) High prevalence of human cytomegalovirus in brain metastases of patients with primary breast and colorectal cancers. Transl Oncol 7: 732-740 doi:10.1016/j.tranon.2014.09.008
41. Jain KK (2018) A Critical Overview of Targeted Therapies for Glioblastoma. Front Oncol 8: 419
doi:10.3389/fonc.2018.00419

42. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Tom S, Idbaih A, Ahluwalia MS,
Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-
Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram
Z (2017) Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance
Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA
318: 2306-2316 doi:10.1001/jama.2017.18718

43. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S,
Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J,
Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M,
Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH (2012)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised
phase III trial of a novel treatment modality. Eur J Cancer 48: 2192-2202
doi:10.1016/j.ejca.2012.04.011

Tables

Table 1. Demographic and clinical characteristics.
| Characteristics               | Recurrent disease |
|------------------------------|-------------------|
|                              | Controls* (n=111) | Valganciclovir (n=29) |
| Age, years                   |                  |                      |
| Median                       | 57               | 54                   |
| Range                        | 24–77            | 21–72                |
| Sex                          |                  |                      |
| Women, n                     | 40 (36%)         | 10 (34.5%)           |
| Men, n                       | 71 (64%)         | 19 (65.5%)           |
| Race                         |                  |                      |
| Caucasian                    | 100%             | 100%                 |
| MGMT promoter status         |                  |                      |
| Methylated                   | 25 (52.1%)       | 6 (35.3%)            |
| Unmethylated                 | 23 (47.9%)       | 11 (64.7%)           |
| IDH1 mutational status       | 2/26 (7.7%)      | 0/6 (0%)             |
| KPS score                    |                  |                      |
| Median                       | 90               | 90                   |
| Range                        | 70-100           | 70-100               |
| Tumor location               |                  |                      |
| Temporal                     | 44 (39.6%)       | 13 (44.8%)           |
| Frontal                      | 28 (25.3)        | 7 (24.1%)            |
| Parietal                     | 27 (24.3%)       | 4 (13.8%)            |
| Occipital                    | 6 (5.4%)         | 3 (10.4%)            |
| Other                        | 6 (5.4%)         | 2 (6.9%)             |
| Primary treatment, n (%)     |                  |                      |
| Surgery                      |                  |                      |
| Radical resection            | 90 (81.1%)       | 20 (69%)             |
| Partial resection or biopsy  | 21 (18.9%)       | 9 (31%)              |
| Second-line therapy          |                  |                      |
| Reoperation                  | 36 (22.4%)       | 13 (44.8%)           |
| Treatment                      | Group 1 | Group 2 |
|-------------------------------|---------|---------|
| Non re-operated               | 75 (67.6%) | 16 (55.2%) |
| Gamma-knife treatment         | 13 (11.7%) | 4 (13.8%) |
| CCNU                          | 92 (82.9%) | 24 (82.8%) |
| Bevacizumab                   | 31 (27.9%) | 13 (44.8%) |

*Controls received standard of care treatment.

**Figures**
A Recurrent GBM, all patients - Survival after recurrence

Estimated survival after recurrence (Panel A) and OS after diagnosis (Panel B) of all 29 patients with recurrent glioblastoma treated with valganciclovir (red) and of 111 contemporary controls who received

![Graph A](image)

No. at Risk

|          | Valganciclovir | Control |
|----------|----------------|---------|
| 0        | 29             | 111     |
| 1        | 17             | 36      |
| 2        | 11             | 11      |
| 3        | 4              | 1        |
| 4        | 3              | 1        |
| 5        | 1              | 1        |
| 6        | 1              | 1        |
| 7        | 0              | 0        |
| 8        | 0              | 0        |
| 9        | 0              | 0        |
| 10       | 0              | 0        |

B Recurrent GBM, all patients - Overall survival

Estimated survival after recurrence (Panel A) and OS after diagnosis (Panel B) of all 29 patients with recurrent glioblastoma treated with valganciclovir (red) and of 111 contemporary controls who received

![Graph B](image)

No. at Risk

|          | Valganciclovir | Control |
|----------|----------------|---------|
| 0        | 29             | 111     |
| 1        | 28             | 96      |
| 2        | 17             | 39      |
| 3        | 11             | 18      |
| 4        | 8              | 5       |
| 5        | 7              | 3       |
| 6        | 4              | 1       |
| 7        | 3              | 1       |
| 8        | 1              | 1       |
| 9        | 1              | 0       |
| 10       | 0              | 0       |
| 11       | 0              | 0       |

Figure 1

Kaplan-Meier Estimates of Survival in Patients with Recurrent Glioblastoma Treated with Valganciclovir and in controls.

Estimated survival after recurrence (Panel A) and OS after diagnosis (Panel B) of all 29 patients with recurrent glioblastoma treated with valganciclovir (red) and of 111 contemporary controls who received
similar second line therapy (blue).

Figure 2

Kaplan-Meier Estimates of Survival in Patients with Recurrent Glioblastoma Treated with Valganciclovir according to second line surgical intervention.
Estimated survival after recurrence of 13 valganciclovir treated patients (red) compared to 35 control patients (blue) who were re-operated at recurrence (Panel A). Panel B includes survival curves of 16 valganciclovir treated patients (red) compared to 76 control patients (blue) who were not re-operated at recurrence.

A Recurrent GBM, patients with methylated MGMT

B Recurrent GBM, patients with unmethylated MGMT

Figure 3
Kaplan-Meier Estimates of Survival in Patients with Recurrent Glioblastoma Treated with Valganciclovir according to methylation status of MGMT promoter gene.

Estimated survival after recurrence of 6 valganciclovir treated patients (red) compared to 25 control patients (blue) with methylated MGMT promoter gene glioblastoma (Panel A) and of 11 valganciclovir treated patients (red) compared to 23 control patients (blue) with unmethylated MGMT promoter gene glioblastoma (Panel B).